Magri Dania, Fancher Tiffany T, Fitzgerald Tamara N, Muto Akihito, Dardik Alan
Department of Surgery, Yale University School of Medicine, New Haven, CT 06519, USA.
Vascular. 2007 Nov-Dec;15(6):384-94. doi: 10.2310/6670.2007.00058.
Endothelial progenitor cells (EPCs) participate in vascular healing during both acute injury and chronic disease. The quantity and quality of circulating EPCs correlate inversely with the severity of vascular disease, such that reduced number and/or function of EPCs are significant independent risk factors for impaired healing capacity, dysfunctional endothelium, and progression of atherosclerosis and vascular disease. EPC therapy assists healing of cardiac and limb ischemia and has great potential for improving the quality of life and longevity of patients with severe cardiovascular and peripheral vascular disease who are not candidates for conventional revascularization procedures. In addition, EPCs can be used to promote vascular graft patency. This review focuses on the characterization of EPCs, positive and negative regulators of EPCs, the role of EPCs in vascular disease, and the potential for EPC therapy to ameliorate the sequelae of severe peripheral vascular disease.
内皮祖细胞(EPCs)在急性损伤和慢性疾病过程中均参与血管修复。循环EPCs的数量和质量与血管疾病的严重程度呈负相关,因此EPCs数量减少和/或功能降低是愈合能力受损、内皮功能障碍以及动脉粥样硬化和血管疾病进展的重要独立危险因素。EPC治疗有助于心脏和肢体缺血的愈合,对于那些不适合传统血运重建手术的严重心血管和外周血管疾病患者,在改善生活质量和延长寿命方面具有巨大潜力。此外,EPCs可用于促进血管移植物通畅。本综述重点关注EPCs的特征、EPCs的正负调节因子、EPCs在血管疾病中的作用以及EPC治疗改善严重外周血管疾病后遗症的潜力。